市場調査レポート
商品コード
1002915

癌免疫アッセイの世界市場 (~2026年):製品&サービス (消耗品・機器・ソフトウェア)・技術 (PCR・NGS・イムノアッセイ)・適応症 (肺癌・乳癌・大腸癌・膀胱癌・黒色腫)・用途 (研究・診断)・地域別

Immuno Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 209 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.14円
癌免疫アッセイの世界市場 (~2026年):製品&サービス (消耗品・機器・ソフトウェア)・技術 (PCR・NGS・イムノアッセイ)・適応症 (肺癌・乳癌・大腸癌・膀胱癌・黒色腫)・用途 (研究・診断)・地域別
出版日: 2021年04月22日
発行: MarketsandMarkets
ページ情報: 英文 209 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要
CAGR 12.5%

世界の癌免疫アッセイの市場規模は予測期間中12.5%のCAGRで推移し、2021年の44億米ドルから、2026年には79億米ドルの規模に成長すると予測されています。医薬品開発におけるコンパニオン診断薬の重要性の高まり、癌の発生率の上昇、標的療法の導入の増加などの要因が同市場の成長を推進しています。一方で、高額な設備投資を必要とし、費用対効果が低いことや、規制や償還に関するシナリオが不利であることなどが市場のさらなる成長を抑制する要因となっています。 製品・サービス別では、消耗品の部門が予測期間中最大の成長を示すと予測されています。

また、用途別では、研究用途の部門が2020年に最大のCAGRを示しています。バイオマーカーを用いた医薬品開発が盛んに行われていることから、同部門の成長が見込まれています。

当レポートでは、世界の癌免疫アッセイの市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、技術・特許の動向、市場規模の推移・予測、製品&サービス・技術・適応症・用途・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 成長推進因子
    • 成長抑制因子
    • 市場機会
    • 市場課題
  • COVID-19の影響
  • 価格分析
  • 特許分析
  • 貿易分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • PESTLE分析
  • 規制状況
  • 技術分析
  • YC-YCCシフト

第6章 市場分析・予測:製品・サービス別

  • 消耗品
  • 機器
  • ソフトウェア・サービス

第7章 市場分析・予測:技術別

  • PCR (ポリメラーゼ連鎖反応)
  • イムノアッセイ
  • 次世代シーケンシング
  • IN SITUハイブリダイゼーション
  • フローサイトメトリー

第8章 市場分析・予測:適応症別

  • 肺癌
  • 乳癌
  • 結腸直腸癌
  • 膀胱癌
  • 黒色腫
  • その他

第9章 市場分析・予測:用途別

  • 研究
  • 臨床診断

第10章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 主要企業の戦略
  • 主要企業の収益シェア分析
  • 市場シェア分析
  • 企業評価クアドラント
  • 新興企業・中小企業の競合リーダーシップマッピング
  • 主要企業の製品・地理的フットプリント分析
  • 競合シナリオ

第12章 企業プロファイル

  • 主要企業
    • THERMO FISHER SCIENTIFIC, INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • ILLUMINA, INC.
    • MERCK MILLIPORE
    • AGILENT TECHNOLOGIES, INC.
    • ABBOTT LABORATORIES, INC.
    • SARTORIUS AG
    • NANOSTRING TECHNOLOGIES, INC.
    • HTG MOLECULAR DIAGNOSTICS, INC.
    • PERKINELMER, INC.
    • QIAGEN N.V.
  • その他の企業
    • BIOMERIEUX SA
    • MYRIAD GENETICS, INC.
    • GUARDANT HEALTH, INC.
    • BIO-RAD LABORATORIES, INC.
    • CHARLES RIVER LABORATORIES, INC.
    • SEEGENE INC.
    • MESO SCALE DIAGNOSTICS, LLC.
    • OLINK
    • ASURAGEN, INC.
    • INVIVOSCRIBE, INC.
    • CREATIVE BIOLABS
    • REACHBIO LLC
    • NMI TECHNOLOGIETRANSFER GMBH

第13章 付録

目次
Product Code: MD 6896

The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4billion in 2021, at a CAGR of 12.5% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand,the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market.

"The consumables segment accounted for the highest growth rate in theimmuno-oncology assaysmarket, by product& service, during the forecast period"

The immuno-oncology assays market is segmented into consumables, instruments, and software & services based on product & service. In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market. The requirement of consumables in large numbers as compared to instruments is the major factor contributing to the growth of this segment.

"Research applications segment accounted for the highest CAGR"

Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics. In 2020, the research applications segmentaccounted for the highest growth rate. This can be attributed to the rising prominence of biomarker-based drug development.

"Asia Pacific: The fastest-growing regionimmuno-oncology assays market"

The global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centeredon China and Japan. Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Agilent Technologies, Inc. (US)
  • Illumina, Inc. (US)
  • NanoString Technologies, Inc. (US)
  • Sartorius AG (Germany)
  • HTG Molecular Diagnostics, Inc. (US)
  • QIAGEN N.V. (Netherlands)
  • Merck Millipore (US)
  • PerkinElmer, Inc. (US)
  • Abbott Laboratories, Inc. (US)
  • Guardant Health, Inc. (US)
  • bioMerieux SA (France)
  • Myriad Genetics, Inc. (US)
  • MESO SCALE DIAGNOSTICS, LLC. (US)
  • Seegene Inc. (South Korea)
  • Bio-Rad Laboratories, Inc. (US)
  • Charles River Laboratories, Inc. (US)
  • Olink (Sweden)
  • ASURAGEN, INC. (US)
  • Invivoscribe, Inc. (US)
  • Creative Biolabs (US)
  • ReachBio LLC (US)
  • NMI Technologietransfer GmbH (Germany)

Research Coverage:

This report provides a detailed picture of the global immuno-oncology assays market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, technology, indication, application, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 IMMUNO-ONCOLOGY ASSAYS MARKET SEGMENTATION
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 2 IMMUNO-ONCOLOGY ASSAYS MARKET: RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
    • FIGURE 4 IMMUNO-ONCOLOGY ASSAYS MARKET: BOTTOM-UP APPROACH
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 IMMUNO-ONCOLOGY ASSAYS MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 COVID-19 HEALTH ASSESSMENT
  • 2.7 COVID-19 ECONOMIC ASSESSMENT
  • 2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
    • FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
    • FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
  • 2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE IMMUNO- ONCOLOGY ASSAYS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 14 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 IMMUNO-ONCOLOGY ASSAYS MARKET OVERVIEW
    • FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
  • 4.2 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
    • FIGURE 16 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
  • 4.3 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
    • FIGURE 17 NGS SEGMENT TO GAIN MARKET SHARE BETWEEN 2021 AND 2026
  • 4.4 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY INDICATION, 2021 VS. 2026
    • FIGURE 18 LUNG CANCER SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • 4.5 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY APPLICATION, 2021 VS. 2026
    • FIGURE 19 RESEARCH APPLICATIONS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
  • 4.6 IMMUNO-ONCOLOGY ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE IMMUNO-ONCOLOGY ASSAYS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 IMMUNO-ONCOLOGY ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of cancer and growing adoption of targeted therapies
    • TABLE 1 GLOBAL CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
    • TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
    • TABLE 3 RESEARCH FUNDING FOR NATIONAL CANCER INSTITUTE, 2016 VS. 2017 VS. 2018 (USD MILLION)
      • 5.2.1.2 Increased demand for personalized medicine
    • TABLE 4 GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005-2018
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Requirement of high capital investments and low cost-benefit ratio
      • 5.2.2.2 Unfavorable regulatory and reimbursement scenario
      • 5.2.2.3 High cost of immunotherapy
    • TABLE 5 COST OF KEYTRUDA, BY COUNTRY (2018)
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets offer lucrative opportunities
      • 5.2.3.2 Growing significance of companion diagnostics
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Low awareness of cancer immunotherapy
  • 5.3 IMPACT OF COVID-19 ON THE IMMUNO-ONCOLOGY ASSAYS MARKET
  • 5.4 PRICING ANALYSIS
    • TABLE 6 PRICE OF IMMUNO-ONCOLOGY ASSAYS (2021)
  • 5.5 PATENT ANALYSIS
  • 5.6 TRADE ANALYSIS
    • 5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 7 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016-2020 (USD MILLION)
    • TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016-2020 (TONS)
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 22 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
  • 5.8 SUPPLY CHAIN ANALYSIS
    • FIGURE 23 DISTRIBUTION-A STRATEGY PREFERRED BY PROMINENT COMPANIES
  • 5.9 ECOSYSTEM ANALYSIS OF THE IMMUNO-ONCOLOGY ASSAYS MARKET
    • FIGURE 24 IMMUNO-ONCOLOGY ASSAYS MARKET: ECOSYSTEM ANALYSIS
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 9 IMMUNO-ONCOLOGY ASSAYS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT OF NEW ENTRANTS
    • 5.10.2 THREAT OF SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF BUYERS
    • 5.10.4 BARGAINING POWER OF SUPPLIERS
    • 5.10.5 DEGREE OF COMPETITION
  • 5.11 PESTLE ANALYSIS
  • 5.12 REGULATORY LANDSCAPE
    • 5.12.1 NORTH AMERICA
      • 5.12.1.1 US
      • 5.12.1.2 CANADA
    • 5.12.2 EUROPE
    • 5.12.3 ASIA PACIFIC
      • 5.12.3.1 JAPAN
      • 5.12.3.2 INDIA
    • 5.12.4 LATIN AMERICA
      • 5.12.4.1 BRAZIL
      • 5.12.4.2 MEXICO
    • 5.12.5 MIDDLE EAST
    • 5.12.6 AFRICA
  • 5.13 TECHNOLOGY ANALYSIS
  • 5.14 YC-YCC SHIFT
    • 5.14.1 YC-YCC SHIFT FOR THE IMMUNO-ONCOLOGY ASSAYS MARKET

6 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 6.2 CONSUMABLES
    • 6.2.1 RECURRENT PURCHASE OF KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
    • TABLE 11 KEY PRODUCTS IN THE CONSUMABLES MARKET
    • TABLE 12 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2019-2026 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED PRODUCTS TO SUPPORT MARKET GROWTH
    • TABLE 13 KEY PRODUCTS IN THE INSTRUMENTS MARKET
    • TABLE 14 IMMUNO-ONCOLOGY ASSAYS MARKET FOR INSTRUMENTS, BY REGION, 2019-2026 (USD MILLION)
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 INCREASING NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS TO SUPPORT MARKET GROWTH
    • TABLE 15 IMMUNO-ONCOLOGY ASSAYS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2019-2026 (USD MILLION)

7 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 16 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
  • 7.2 POLYMERASE CHAIN REACTION
    • 7.2.1 EMERGENCE OF ADVANCED PCR TECHNOLOGIES TO SUPPORT MARKET GROWTH
    • TABLE 17 IMMUNO-ONCOLOGY ASSAYS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 IMMUNOASSAY
    • 7.3.1 IMMUNOASSAYS HAVE THE POTENTIAL TO REDUCE CANCER MORTALITY RATE BY FACILITATING THE DIAGNOSIS OF CANCER AT AN EARLY STAGE
    • TABLE 18 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IMMUNOASSAY, BY REGION, 2019-2026 (USD MILLION)
  • 7.4 NEXT-GENERATION SEQUENCING
    • 7.4.1 NGS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
    • TABLE 19 IMMUNO-ONCOLOGY ASSAYS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2019-2026 (USD MILLION)
  • 7.5 IN SITU HYBRIDIZATION
    • 7.5.1 HIGH DEMAND FOR IN SITU HYBRIDIZATION IN THE DIAGNOSIS OF SMALL TUMORS TO DRIVE MARKET GROWTH
    • TABLE 20 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019-2026 (USD MILLION)
  • 7.6 FLOW CYTOMETRY
    • 7.6.1 GROWING INCIDENCE & PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH
    • TABLE 21 IMMUNO-ONCOLOGY ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2019-2026 (USD MILLION)

8 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION

  • 8.1 INTRODUCTION
    • TABLE 22 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
  • 8.2 LUNG CANCER
    • 8.2.1 INCREASING RESEARCH ON LUNG CANCER BIOMARKERS TO DRIVE MARKET GROWTH
    • TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2018 VS. 2025
    • TABLE 24 IMMUNO-ONCOLOGY ASSAYS MARKET FOR LUNG CANCER, BY REGION, 2019-2026 (USD MILLION)
  • 8.3 BREAST CANCER
    • 8.3.1 INCREASING GOVERNMENT FUNDING FOR BREAST CANCER RESEARCH TO DRIVE MARKET GROWTH
    • TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2018 VS. 2025
    • TABLE 26 IMMUNO-ONCOLOGY ASSAYS MARKET FOR BREAST CANCER, BY REGION, 2019-2026 (USD MILLION)
  • 8.4 COLORECTAL CANCER
    • 8.4.1 INCREASING PREVALENCE OF COLORECTAL CANCER TO PROPEL MARKET GROWTH
    • FIGURE 25 COLORECTAL CANCER INCIDENCE RATE IN KEY COUNTRIES (2018)
    • TABLE 27 IMMUNO-ONCOLOGY ASSAYS MARKET FOR COLORECTAL CANCER, BY REGION, 2019-2026 (USD MILLION)
  • 8.5 BLADDER CANCER
    • 8.5.1 BLADDER CANCER SEGMENT TO WITNESS SLOWER GROWTH OWING TO THE LIMITED ADOPTION OF IMMUNO-ONCOLOGY ASSAYS
    • TABLE 28 IMMUNO-ONCOLOGY ASSAYS MARKET FOR BLADDER CANCER, BY REGION, 2019-2026 (USD MILLION)
  • 8.6 MELANOMA
    • 8.6.1 GROWING INCIDENCE OF MELANOMA TO DRIVE THE DEMAND FOR IMMUNO-ONCOLOGY ASSAYS
    • TABLE 29 IMMUNO-ONCOLOGY ASSAYS MARKET FOR MELANOMA, BY REGION, 2019-2026 (USD MILLION)
  • 8.7 OTHER CANCERS
    • TABLE 30 GLOBAL CANCER INCIDENCE, 2020
    • TABLE 31 IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER CANCERS, BY REGION, 2019-2026 (USD MILLION)

9 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 32 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 9.2 RESEARCH APPLICATIONS
    • 9.2.1 RISING PROMINENCE OF BIOMARKER-BASED DRUG DEVELOPMENT TO DRIVE THE RESEARCH APPLICATIONS MARKET
    • TABLE 33 IMMUNO-ONCOLOGY ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)
  • 9.3 CLINICAL DIAGNOSTICS
    • 9.3.1 BENEFITS OF IMMUNO-ONCOLOGY ASSAYS ARE DRIVING THEIR ADOPTION IN CLINICAL DIAGNOSTICS
    • TABLE 34 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2019-2026 (USD MILLION)

10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 35 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 26 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012-2035
    • FIGURE 27 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT
    • TABLE 36 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 37 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 38 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 39 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 40 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 The US dominates the North American immuno- oncology assays market
    • TABLE 41 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 42 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 43 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 44 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 45 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing government initiatives focused on promoting research to support market growth
    • TABLE 46 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 47 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 48 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 49 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 50 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 10.3 EUROPE
    • FIGURE 28 EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035
    • TABLE 51 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 52 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 53 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 54 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 55 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany to dominate the European immuno-oncology assays market during the forecast period
    • TABLE 56 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 57 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 58 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 59 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 60 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.3.2 ITALY
      • 10.3.2.1 Increasing life science R&D in Italy to drive market growth
    • TABLE 61 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 62 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 63 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 64 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 65 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing government funding for research to support market growth in France
    • TABLE 66 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 67 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 68 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 69 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 70 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.3.4 UK
      • 10.3.4.1 Growth in the country's life science industry and increasing focus on research to propel market growth
    • TABLE 71 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 72 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 73 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 74 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Increasing focus on the advancement of personalized medicine in Spain to drive market growth
    • TABLE 75 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 76 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 77 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 78 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 79 ROE: CANCER INCIDENCE, BY COUNTRY, 2020 VS. 2040
    • TABLE 80 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2020 VS. 2040
    • TABLE 81 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 82 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 83 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 84 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 29 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012-2035
    • FIGURE 30 ASIA PACIFIC: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT
    • TABLE 85 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 86 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 87 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 88 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 89 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 China accounts for the largest share of the APAC market
    • TABLE 90 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 91 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 92 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 93 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 94 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Research initiatives toward the development of precision medicine are supporting market growth in Japan
    • TABLE 95 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 96 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 97 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 98 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 99 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Increased demand for early cancer diagnosis to support market growth in India
    • TABLE 100 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 101 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 102 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 103 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 104 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 105 ROAPAC: INCIDENCE OF CANCER, BY COUNTRY, 2020 VS. 2040
    • TABLE 106 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 107 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 108 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 109 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 GROWING CONTRACT RESEARCH AND MANUFACTURING ACTIVITIES IN THE REGION TO SUPPORT MARKET GROWTH
    • TABLE 110 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 111 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 112 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 113 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE THE MARKET GROWTH
    • TABLE 114 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 115 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 116 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 117 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 31 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE IMMUNO-ONCOLOGY ASSAYS MARKET
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 32 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER (2020)
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 LIST OF EVALUATED VENDORS
    • 11.5.2 STARS
    • 11.5.3 EMERGING LEADERS
    • 11.5.4 PERVASIVE PLAYERS
    • 11.5.5 PARTICIPANTS
    • FIGURE 33 IMMUNO-ONCOLOGY ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
  • 11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 34 IMMUNO-ONCOLOGY ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
  • 11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
    • FIGURE 35 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE IMMUNO-ONCOLOGY ASSAYS MARKET
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 MARKET EVALUATION FRAMEWORK, 2018-2020
    • 11.8.2 PRODUCT LAUNCHES & REGULATORY APPROVALS
    • TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
    • 11.8.3 DEALS
    • TABLE 119 KEY DEALS
    • 11.8.4 OTHER DEVELOPMENTS
    • TABLE 120 OTHER KEY DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)**
    • 12.1.1 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 121 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.2 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 122 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
    • FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
    • 12.1.3 ILLUMINA, INC.
    • TABLE 123 ILLUMINA, INC.: BUSINESS OVERVIEW
    • FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.4 MERCK MILLIPORE
    • TABLE 124 MERCK MILLIPORE: BUSINESS OVERVIEW
    • FIGURE 39 MERCK MILLIPORE: COMPANY SNAPSHOT (2020)
    • 12.1.5 AGILENT TECHNOLOGIES, INC.
    • TABLE 125 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.6 ABBOTT LABORATORIES, INC.
    • TABLE 126 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 41 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.7 SARTORIUS AG
    • TABLE 127 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 42 SARTORIUS AG: COMPANY SNAPSHOT (2020)
    • 12.1.8 NANOSTRING TECHNOLOGIES, INC.
    • TABLE 128 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 43 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.9 HTG MOLECULAR DIAGNOSTICS, INC.
    • TABLE 129 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW
    • FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2019)
    • 12.1.10 PERKINELMER, INC.
    • TABLE 130 PERKINELMER, INC.: BUSINESS OVERVIEW
    • FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.11 QIAGEN N.V.
    • TABLE 131 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
  • 12.2 OTHER PLAYERS
    • 12.2.1 BIOMERIEUX SA
    • TABLE 132 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 47 BIOMERIEUX SA: COMPANY SNAPSHOT (2020)
    • 12.2.2 MYRIAD GENETICS, INC.
    • TABLE 133 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
    • FIGURE 48 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2019)
    • 12.2.3 GUARDANT HEALTH, INC.
    • TABLE 134 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
    • FIGURE 49 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2019)
    • 12.2.4 BIO-RAD LABORATORIES, INC.
    • 12.2.5 CHARLES RIVER LABORATORIES, INC.
    • 12.2.6 SEEGENE INC.
    • TABLE 135 SEEGENE INC.: BUSINESS OVERVIEW
    • 12.2.7 MESO SCALE DIAGNOSTICS, LLC.
    • TABLE 136 MESO SCALE DIAGNOSTICS, LLC.: BUSINESS OVERVIEW
    • 12.2.8 OLINK
    • 12.2.9 ASURAGEN, INC.
    • 12.2.10 INVIVOSCRIBE, INC.
    • 12.2.11 CREATIVE BIOLABS
    • 12.2.12 REACHBIO LLC
    • 12.2.13 NMI TECHNOLOGIETRANSFER GMBH
  • *Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies

13 APPENDIX

  • 13.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 AVAILABLE CUSTOMIZATIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS